Edition:
United States

Ligand Pharmaceuticals Inc (LGND.O)

LGND.O on Consolidated Issue listed on NASDAQ Global Market

143.09USD
18 Oct 2017
Change (% chg)

$0.94 (+0.66%)
Prev Close
$142.15
Open
$142.13
Day's High
$143.09
Day's Low
$141.79
Volume
20,062
Avg. Vol
244,937
52-wk High
$144.34
52-wk Low
$87.50

Latest Key Developments (Source: Significant Developments)

Ligand to acquire Crystal Bioscience
Wednesday, 4 Oct 2017 04:05pm EDT 

Oct 4 (Reuters) - Ligand Pharmaceuticals Inc :Ligand to acquire Crystal Bioscience, the leader in chicken-derived fully-human antibody generation, for $25 million in cash plus additional potential payments.Ligand Pharmaceuticals Inc - ‍transaction expected to be accretive to revenue and earnings beginning in 2018​.Ligand Pharmaceuticals Inc - Ligand will pay Crystal shareholders $25 million in cash at closing, up to an additional $10.5 million of success-based milestones.Ligand Pharmaceuticals Inc says ‍including acquisition, Ligand now expects 2017 total revenues to be at least $134 million​.Ligand Pharmaceuticals Inc says estimates with revenue of $134 million, FY 2017 adjusted earnings per share would be approximately $2.93​.Ligand Pharmaceuticals Inc expects 2017 earnings per share would be approximately $2.93.  Full Article

Ligand Pharmaceuticals Q2 earnings per share $0.26
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Ligand Pharmaceuticals Inc :Ligand reports second quarter 2017 financial results.Q2 adjusted earnings per share $0.67.Q2 earnings per share $0.26.Q2 earnings per share view $0.46 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue at least $133 million.  Full Article

Ligand partner Melinta Therapeutics says FDA approves antibiotic Baxdela
Tuesday, 20 Jun 2017 09:00am EDT 

June 20 (Reuters) - Ligand Pharmaceuticals Inc :ligand’s partner melinta therapeutics announces u.s. Fda approval of baxdela™ (delafloxacin) for acute bacterial skin and skin structure infections (absssi).Ligand pharmaceuticals inc -as a result of approval, ligand has earned a $1.5 million milestone payment and will earn a 2.5% royalty on baxdela iv sales.  Full Article

Ligand enters into worldwide Omniab platform license agreement with Surface Oncology
Thursday, 1 Jun 2017 09:00am EDT 

June 1 (Reuters) - Ligand Pharmaceuticals Inc :Ligand enters into worldwide Omniab® platform license agreement with Surface Oncology.Has entered into a worldwide license agreement with Surface Oncology.Ligand Pharmaceuticals - under license, Surface will use omnirat, omnimouse, omniflic platforms to discover fully human mono- and bispecific antibodies.Surface will be responsible for all costs related to programs.  Full Article

Ligand enters into worldwide omniab platform license agreement with Xcella Biosciences
Tuesday, 30 May 2017 09:00am EDT 

May 30 (Reuters) - Ligand Pharmaceuticals Inc :Ligand enters into worldwide omniab® platform license agreement with xcella biosciences.Under license, xcella will be able to use omnirat, omnimouse and omniflic platforms.Ligand Pharmaceuticals - co is eligible to receive development, regulatory milestone payments, royalties for each product incorporating an omniab antibody.Xcella will be responsible for all costs related to the omni programs.  Full Article

Ligand reports Q1 earnings per share $0.22
Tuesday, 9 May 2017 04:01pm EDT 

May 9 (Reuters) - Ligand Pharmaceuticals Inc :Ligand reports first quarter 2017 financial results.Q1 adjusted earnings per share $0.57.Q1 earnings per share $0.22.Q1 earnings per share view $0.63 -- Thomson Reuters I/B/E/S.Ligand Pharmaceuticals Inc - Total revenues for Q1 of 2017 were $29.3 million, compared with $29.6 million for same period in 2016.Ligand Pharmaceuticals Inc - As of March 31, 2017, Ligand had cash, cash equivalents and short-term investments of $159.4 million.Ligand Pharmaceuticals Inc - During 2017, Ligand estimates it could potentially receive up to an additional $24 million of contract payments.Ligand Pharmaceuticals Inc sees 2017 core revenue of $130 million.Ligand Pharmaceuticals Inc sees 2017 adjusted earnings per diluted share would be approximately $2.70.Q1 revenue view $31.2 million -- Thomson Reuters I/B/E/S.FY2017 revenue view $131.8 million -- Thomson Reuters I/B/E/S.  Full Article

Ligand announces licensing partner Janssen has filed an IND for an antibody discovered using the OmniAB Technology
Tuesday, 28 Mar 2017 09:00am EDT 

Ligand Pharmaceuticals Inc : Ligand announces licensing partner janssen has filed an IND for an antibody discovered using the OmniAB Technology .Ligand Pharmaceuticals Inc - IND filing results in $1 million milestone payment to Ligand.  Full Article

Enrollment completed in Ligand's phase 2 trial of lgd-6972 in type 2 diabetes
Monday, 27 Feb 2017 09:00am EST 

Ligand Pharmaceuticals Inc : Enrollment completed in Ligand's phase 2 trial of lgd-6972 in type 2 diabetes .Ligand Pharmaceuticals Inc - company expects to report topline results in September 2017.  Full Article

Ligand Pharmaceuticals Q4 adjusted earnings per share $0.74
Thursday, 23 Feb 2017 04:01pm EST 

Ligand Pharmaceuticals Inc : Ligand reports fourth quarter and full year 2016 financial results . Q4 adjusted earnings per share $0.74 . Q4 GAAP loss per share $0.15 . Q4 revenue $38.2 million versus I/B/E/S view $40.3 million . Q4 earnings per share view $1.19 -- Thomson Reuters I/B/E/S . Ligand Pharmaceuticals says estimates 2017 core revenue to include royalties of about $87 million, material sales of about $23 million, contract payments of at least $20 million .Ligand Pharmaceuticals Inc says estimates that cash expenses for 2017 will be in range of $28 million to $30 million.  Full Article

Ligand expects revenue related to Captisol material sales to be unchanged
Wednesday, 18 Jan 2017 05:57pm EST 

Ligand Pharmaceuticals Inc : Ligand Pharmaceuticals - companies must adopt standard issued by FASB in may 2014 after january 1, 2017 and no later than january 1, 2018 . Ligand Pharmaceuticals Inc- company anticipates the standard will have a material impact on its consolidated financial statements - SEC filing . Ligand Pharmaceuticals Inc - expects revenue related to Captisol material sales to remain unchanged .Ligand Pharma-most significant impact from standards relates to accounting for revenues related to royalties, contingent "milestone" based payments.  Full Article

BRIEF-Ligand to acquire Crystal Bioscience

* Ligand to acquire Crystal Bioscience, the leader in chicken-derived fully-human antibody generation, for $25 million in cash plus additional potential payments